Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.5000 on 2017-12-15

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.5000 on 2017-12-15

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert
PAST TOP PICK
Abbott Labs(ABT-N) 

October 10, 2017

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

biotechnology/pharmaceutical

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$55.400
Owned Owned
Yes

BUY on WEAKNESS
Abbott Labs(ABT-N) 

June 15, 2017

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.

biotechnology/pharmaceutical

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$48.120
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

May 17, 2017

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

biotechnology/pharmaceutical

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$43.080
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

May 10, 2017

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$44.500
Owned Owned
No

BUY
Abbott Labs(ABT-N) 

March 21, 2017

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.

biotechnology/pharmaceutical

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.

biotechnology/pharmaceutical
David Dietze

Founder, Pres. & Chief Investment Strategist, Point View Wealth Ma...

PricePrice
$44.800
Owned Owned
Unknown

COMMENT
Abbott Labs(ABT-N) 

February 22, 2017

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$45.010
Owned Owned
Unknown

WAIT
Abbott Labs(ABT-N) 

September 13, 2016

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.

biotechnology/pharmaceutical

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$40.640
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

August 17, 2016

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)

biotechnology/pharmaceutical

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)

biotechnology/pharmaceutical
Bruce Tatters

Founding Partner and CIO, Triumph Asset Manage...

PricePrice
$44.680
Owned Owned
Unknown

DON'T BUY
Abbott Labs(ABT-N) 

July 28, 2016

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.

biotechnology/pharmaceutical

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.

biotechnology/pharmaceutical
Andy Nasr

VP & Investment Strategist, Sentry Investments...

PricePrice
$44.450
Owned Owned
No

COMMENT
Abbott Labs(ABT-N) 

June 22, 2016

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$38.740
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

June 14, 2016

Acquiring St. Jude Medical to enhance their stent products, and Alere, which is a diagnostic company. The stock pulled back when they announced the St. Jude acquisition, as it is quite large. The company will probably have to issue some equity to fund both acquisitions. She really likes management. This is an attractive entry point.

biotechnology/pharmaceutical

Acquiring St. Jude Medical to enhance their stent products, and Alere, which is a diagnostic company. The stock pulled back when they announced the St. Jude acquisition, as it is quite large. The company will probably have to issue some equity to fund both acquisitions. She really likes management. This is an attractive entry point.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$37.660
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

June 1, 2016

Has not performed very well of late. He likes it going forward as well as their acquisition of St. Jude’s Medical, which will be accretive to the bottom line. This would be a nice time to pick up some shares.

biotechnology/pharmaceutical

Has not performed very well of late. He likes it going forward as well as their acquisition of St. Jude’s Medical, which will be accretive to the bottom line. This would be a nice time to pick up some shares.

biotechnology/pharmaceutical
Matthew McCall

President, Penn Financial Group...

PricePrice
$39.500
Owned Owned
Unknown

COMMENT
Abbott Labs(ABT-N) 

May 18, 2016

Emerging markets represents about 40% of their earnings. Have a very strong branded generic division and a lot of that is in the emerging-market, so currency has been a huge head wind for them. Also, have a leading adult and infant nutritional business as well as medical devices. There was some concern that the medical device area was not growing as fast as some of their other businesses. Management is quite competent they can get things improving.

biotechnology/pharmaceutical

Emerging markets represents about 40% of their earnings. Have a very strong branded generic division and a lot of that is in the emerging-market, so currency has been a huge head wind for them. Also, have a leading adult and infant nutritional business as well as medical devices. There was some concern that the medical device area was not growing as fast as some of their other businesses. Management is quite competent they can get things improving.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$37.750
Owned Owned
Yes

DON'T BUY
Abbott Labs(ABT-N) 

May 11, 2016

Healthcare is a great sector, but the worst performing one year-to-date. Politicians are talking about capping prices for healthcare manufacturers, which doesn’t help. More importantly, Medicare and Medicaid US administrations are trying to cap prices and this one is being hit particularly hard. There are better names in this space.

biotechnology/pharmaceutical

Healthcare is a great sector, but the worst performing one year-to-date. Politicians are talking about capping prices for healthcare manufacturers, which doesn’t help. More importantly, Medicare and Medicaid US administrations are trying to cap prices and this one is being hit particularly hard. There are better names in this space.

biotechnology/pharmaceutical
John Burke

CEO & CIO, Burke Financial Stra...

PricePrice
$38.010
Owned Owned
Unknown

COMMENT
Abbott Labs(ABT-N) 

February 9, 2016

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.

biotechnology/pharmaceutical

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$37.000
Owned Owned
Yes

BUY on WEAKNESS
Abbott Labs(ABT-N) 

February 4, 2016

He likes it.  Everything under healthcare has been under pressure.  Model $39 with a 3% upside.  At $31 he would be very excited.

biotechnology/pharmaceutical

He likes it.  Everything under healthcare has been under pressure.  Model $39 with a 3% upside.  At $31 he would be very excited.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$38.010
Owned Owned
Unknown

COMMENT
Abbott Labs(ABT-N) 

September 17, 2015

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

biotechnology/pharmaceutical

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Manag...

PricePrice
$44.240
Owned Owned
No

COMMENT
Abbott Labs(ABT-N) 

May 5, 2015

Right now this is more if a consumer and diagnostic company. Has done quite well. Is very, very steady. Have increased their dividends 43 years in a row. A nice holding for somebody who wants to buy something and just stay with it over the long-term. However, the valuation is not cheap. Well-managed and should do well over the long-term.

biotechnology/pharmaceutical

Right now this is more if a consumer and diagnostic company. Has done quite well. Is very, very steady. Have increased their dividends 43 years in a row. A nice holding for somebody who wants to buy something and just stay with it over the long-term. However, the valuation is not cheap. Well-managed and should do well over the long-term.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$46.850
Owned Owned
No

BUY on WEAKNESS
Abbott Labs(ABT-N) 

April 27, 2015

He would wait for some sort of correction. Likes this. It is a leader in its field.

biotechnology/pharmaceutical

He would wait for some sort of correction. Likes this. It is a leader in its field.

biotechnology/pharmaceutical
Peter Brieger

Chairman & Chief Executive Officer, GlobeInvestment Capi...

PricePrice
$47.490
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

March 5, 2015

Has a really good upward trend. It is a little above trend right now. Great long-term chart. Healthcare is a great long-term trend that we are in, and you can’t go wrong. It will probably come back a little bit, but nothing to worry about.

biotechnology/pharmaceutical

Has a really good upward trend. It is a little above trend right now. Great long-term chart. Healthcare is a great long-term trend that we are in, and you can’t go wrong. It will probably come back a little bit, but nothing to worry about.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc....

PricePrice
$47.440
Owned Owned
No

PAST TOP PICK
Abbott Labs(ABT-N) 

November 11, 2014

(A Top Pick Oct 29/13. Up 22.2%.) A diversified health company. About 40% of their branded generic business is in emerging markets. They expect to increase that percentage. Also, a large player in the nutritional business. Their 3rd division is medical devices and diagnostics.

biotechnology/pharmaceutical

(A Top Pick Oct 29/13. Up 22.2%.) A diversified health company. About 40% of their branded generic business is in emerging markets. They expect to increase that percentage. Also, a large player in the nutritional business. Their 3rd division is medical devices and diagnostics.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$44.250
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

October 14, 2014

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.

biotechnology/pharmaceutical

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$41.060
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

October 7, 2014

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.

biotechnology/pharmaceutical

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$41.460
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

September 17, 2014

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.

biotechnology/pharmaceutical

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$43.380
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

August 29, 2014

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.

biotechnology/pharmaceutical

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.

biotechnology/pharmaceutical
Jennifer Radman

VP & Sr. Portfolio Manager, Caldwell Investment ...

PricePrice
$42.240
Owned Owned
No

PAST TOP PICK
Abbott Labs(ABT-N) 

July 8, 2014

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out.  This is where the growth is.  They have branded generics which are a growth area in emerging markets.  The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.

biotechnology/pharmaceutical

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out.  This is where the growth is.  They have branded generics which are a growth area in emerging markets.  The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$41.050
Owned Owned
Yes

DON'T BUY
Abbott Labs(ABT-N) 

April 9, 2014

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.

biotechnology/pharmaceutical

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Manag...

PricePrice
$37.630
Owned Owned
No

BUY
Abbott Labs(ABT-N) 

February 18, 2014

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

biotechnology/pharmaceutical

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns...

PricePrice
$38.930
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

February 7, 2014

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.

biotechnology/pharmaceutical

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.

biotechnology/pharmaceutical
Michael Bowman

Portfolio Manager, Wickham Investment M...

PricePrice
$37.180
Owned Owned
Unknown

PAST TOP PICK
Abbott Labs(ABT-N) 

February 4, 2014

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.

biotechnology/pharmaceutical

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$36.250
Owned Owned
Yes

DON'T BUY
Abbott Labs(ABT-N) 

January 29, 2014

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.

biotechnology/pharmaceutical

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$35.850
Owned Owned
No

BUY
Abbott Labs(ABT-N) 

January 2, 2014

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.

biotechnology/pharmaceutical

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$38.230
Owned Owned
No

COMMENT
Abbott Labs(ABT-N) 

December 23, 2013

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.

biotechnology/pharmaceutical

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Manage...

PricePrice
$38.440
Owned Owned
No

TOP PICK
Abbott Labs(ABT-N) 

December 9, 2013

Spun off drug side.  It is medical devices and has been one of the most consistent growers over the last decade.  Reasonably priced, 2.5% yield.

biotechnology/pharmaceutical

Spun off drug side.  It is medical devices and has been one of the most consistent growers over the last decade.  Reasonably priced, 2.5% yield.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs...

PricePrice
$37.200
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

November 29, 2013

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company

biotechnology/pharmaceutical

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$38.190
Owned Owned
No

TOP PICK
Abbott Labs(ABT-N) 

November 1, 2013

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

biotechnology/pharmaceutical

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns...

PricePrice
$36.960
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

October 30, 2013

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.

biotechnology/pharmaceutical

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Manageme...

PricePrice
$36.940
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

October 29, 2013

Adult and infant nutritionals.  Generics, very emerging market focused, diversified.  Good earnings growth going forward.  Very shareholder friendly.  Increasing dividend should attract more shareholders. 

biotechnology/pharmaceutical

Adult and infant nutritionals.  Generics, very emerging market focused, diversified.  Good earnings growth going forward.  Very shareholder friendly.  Increasing dividend should attract more shareholders. 

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$37.280
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

October 10, 2013

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well.  He sold ABT.

biotechnology/pharmaceutical

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well.  He sold ABT.

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Ma...

PricePrice
$33.640
Owned Owned
No

HOLD
Abbott Labs(ABT-N) 

October 4, 2013

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.

biotechnology/pharmaceutical

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$33.560
Owned Owned
No

TOP PICK
Abbott Labs(ABT-N) 

September 19, 2013

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

biotechnology/pharmaceutical

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns...

PricePrice
$35.340
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

September 18, 2013

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.

biotechnology/pharmaceutical

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc....

PricePrice
$35.650
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

July 29, 2013

Just moved up stop loss to $34.90 (200 day moving average).  They are in the right space.  Nutritional component looks to be just in the beginning of a long term uptrend.

biotechnology/pharmaceutical

Just moved up stop loss to $34.90 (200 day moving average).  They are in the right space.  Nutritional component looks to be just in the beginning of a long term uptrend.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc....

PricePrice
$36.740
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

July 9, 2013

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

biotechnology/pharmaceutical

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$34.740
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

May 31, 2013

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

biotechnology/pharmaceutical

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs...

PricePrice
$36.670
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

May 9, 2013

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out.  This is about the best performing part of the market this year.  Good dividend growth and very strong balance sheets. 

biotechnology/pharmaceutical

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out.  This is about the best performing part of the market this year.  Good dividend growth and very strong balance sheets. 

biotechnology/pharmaceutical
David Burrows

President & Chief Investment Strategist, Barometer Capital Ma...

PricePrice
$36.180
Owned Owned
Yes

PAST TOP PICK
Abbott Labs(ABT-N) 

April 15, 2013

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

biotechnology/pharmaceutical

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs...

PricePrice
$36.130
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

April 9, 2013

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

biotechnology/pharmaceutical

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$36.660
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

March 7, 2013

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.

biotechnology/pharmaceutical

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.

biotechnology/pharmaceutical
Patrick Horan

Portfolio Manager, Agilith Capital Inc...

PricePrice
$34.430
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

February 26, 2013

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

biotechnology/pharmaceutical

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Manage...

PricePrice
$34.060
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

February 25, 2013

She sold ABv.  But ABT-N has a very good basic business.  Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon. 

biotechnology/pharmaceutical

She sold ABv.  But ABT-N has a very good basic business.  Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon. 

biotechnology/pharmaceutical
Chyanne Fickes

Vice President of Investments, Stone Funds...

PricePrice
$34.270
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

February 12, 2013

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

biotechnology/pharmaceutical

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital ...

PricePrice
$34.300
Owned Owned
Yes

COMMENT
Abbott Labs(ABT-N) 

February 5, 2013

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

biotechnology/pharmaceutical

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

biotechnology/pharmaceutical
John O'Connell, CFA

Chairman and CEO, Davis Rea...

PricePrice
$33.840
Owned Owned
Unknown

HOLD
Abbott Labs(ABT-N) 

January 10, 2013

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

biotechnology/pharmaceutical

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$33.850
Owned Owned
No

BUY
Abbott Labs(ABT-N) 

December 3, 2012

It already had a bump up in price, but he is planning on holding both parts.  Buying for new clients.

biotechnology/pharmaceutical

It already had a bump up in price, but he is planning on holding both parts.  Buying for new clients.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Manage...

PricePrice
$64.290
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

November 30, 2012

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

biotechnology/pharmaceutical

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

biotechnology/pharmaceutical
Chyanne Fickes

Vice President of Investments, Stone Funds...

PricePrice
$65.000
Owned Owned
Yes

TOP PICK
Abbott Labs(ABT-N) 

November 26, 2012

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.

biotechnology/pharmaceutical

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$64.360
Owned Owned
Yes

SELL
Abbott Labs(ABT-N) 

November 21, 2012

(Market Call Minute) Would sell on the split.  It is too complicated to be there with the split.

biotechnology/pharmaceutical

(Market Call Minute) Would sell on the split.  It is too complicated to be there with the split.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

PricePrice
$63.330
Owned Owned
Unknown

TOP PICK
Abbott Labs(ABT-N) 

November 19, 2012

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

biotechnology/pharmaceutical

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Manageme...

PricePrice
$62.920
Owned Owned
Yes

BUY
Abbott Labs(ABT-N) 

November 12, 2012

(Market Call Minute) Sell off is because it is going to split itself up which will realize value.

biotechnology/pharmaceutical

(Market Call Minute) Sell off is because it is going to split itself up which will realize value.

biotechnology/pharmaceutical
Gavin Graham

Trustee, Pointbreak ETFs...

PricePrice
$64.870
Owned Owned
Yes

Showing 1 to 60 of 106 entries
<< < 1 2 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company